VJHemOnc is committed to improving our service to you

CAR-T ICU 2019 | CAR-T and neurotoxicity: frequency and management

VJHemOnc is committed to improving our service to you

Robert Hadden

Robert Hadden, BM BCh, FRCP, PhD, King’s College Hospital, London, UK, gives an overview of the adverse neurological events that can potentially result from CAR T-cell therapy. This interview took place at the CAR-T Cell Therapy and the ICU meeting in London, UK, which was organized by EuroCARTForce.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter